To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Adjuvant Tamoxifen Plus O… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

Journal article
Authors Karin Ribi
Weixiu Luo
Jürg Bernhard
Prudence A Francis
Harold J Burstein
Eva Ciruelos
Meritxell Bellet
Lorenzo Pavesi
Ana Lluch
Marilena Visini
Vani Parmar
Carlo Tondini
Pierre Kerbrat
Antonia Perelló
Patrick Neven
Roberto Torres
Davide Lombardi
Fabio Puglisi
Per Karlsson
Thomas Ruhstaller
Marco Colleoni
Alan S Coates
Aron Goldhirsch
Karen N Price
Richard D Gelber
Meredith M Regan
Gini F Fleming
Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume 34
Issue 14
Pages 1601-1610
ISSN 1527-7755
Publication year 2016
Published at Institute of Clinical Sciences, Department of Oncology
Pages 1601-1610
Language en
Links dx.doi.org/10.1200/JCO.2015.64.8675
Subject categories Cancer and Oncology

Abstract

The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?